NY-ACTTRADER
2.11.2021 10:58:05 CET | Business Wire | Press release
ActTrader, now a Finvasia Group Company, won this year’s best Multi-Asset Platform award at largest trading event in the MENA region - The Forex Expo, Dubai 2021. The award recognises businesses that push the boundaries of innovation in the Fintech space.
ActTrader provides customised solutions and dedicated technical infrastructure to some of the biggest forex brokers, hedge funds, ECN venues, multi-asset exchanges and financial institutions. They offer adaptive trading technology that works seamlessly through a single feature-rich application, eliminating the need of integrating with third-party applications.
When contacted, Sarvjeet Singh, co-founder Finvasia said he feels humbled to have achieved this milestone within the first year of their acquisition of ActTrader. "We envisage to build innovative technology solutions that meet the evolving needs of current and future needs of financial institutions," he further added.
The Fore Expo is one of the biggest trading event that hosts prestigious brokers, technology providers, financial institutions, banks, retail traders and media houses from the financial services industry. With more than 7000 in attendance, it is a place for people from the finance industry to coming together in one place.
"ActTrader has been making a buzz ever since its inception in 2000. It has helped thousands of multi-asset brokers and financial institutions globally to revolutionise their trading operations, hedge their risk, and yield profits with its tailor-made solutions." - Ilya Sorokin, Founder & CEO, ActTrader.
About ActTrader
ActTrader is a leading provider of multi-asset trading technologies with award-winning products including the state-of-the-art trading platform, order execution engine, CRM solutions, Auto Trading Algorithms, White Label Solutions, STP Liquidity through FIX API, Multi-platform bridge, AI-based social trading, crypto exchange, and other value-added services.
To expand the company’s B2B offerings, ActTrader joined forces with Finvasia Group- a multinational organisation that owns various brands in the financial services, healthcare, real estate, blockchain, and technology sectors.
Know more: https://acttrader.com/
About FINVASIA Group
FINVASIA is a multi-disciplinary, multinational organisation registered with regulatory bodies across the world, via its subsidiaries and sister concerns, in various capacities including SEC, USA (152771), CYSEC (367/18), FCA (850138), BaFin (157125), ACPR (85051), CONSOB (5151), CNVM (4892), Finanstilsynet (FT00118545) and more.
In India, Finvasia is registered with the Reserve Bank of India as an NBFC, NSE as a Professional Clearing member (M51912), BSE (4043), MCX (55135), and NCDEX as Trading Member (01259), AMFI (103331) and CDSL as Depository Participant (12084300).
Know more: https://finvasia.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20211102005647/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dubai Culture Opens Registration for ISEA2026 Dubai26.10.2026 13:09:00 CET | Press release
Dubai Culture and Arts Authority (Dubai Culture) has opened registration for the 31st International Symposium on Electronic/Emerging Art (ISEA2026 Dubai), taking place from 6 to 15 November 2026 under the theme ‘ELYAH: Constellating Place, Data and Identity’. The symposium will be the largest edition to date, bringing together artists, researchers, and innovators from around the world to explore the intersection of art, science, and technology and exchange perspectives on the future of contemporary creative practice. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026652826/en/ Dubai Culture Opens Registration for ISEA2026 Dubai (Graphic: AETOSWire) The event supports Dubai Culture’s efforts to advance the digital arts ecosystem, deliver on its Digital Arts Roadmap objectives, and empower local talent. It also reinforces Dubai’s position as a global cultural reference, a leader in innovation, a driver of the creative econo
Agendia Unveils Clinical Validation of AI-Driven Digital Pathology Approach26.10.2026 13:00:00 CET | Press release
The investigational AI-driven digital assay demonstrated high concordance with MammaPrint results in the prospective RASTER cohort of 372 early-stage breast cancer patients with a median follow-up of 10.3 years Agendia, Inc., a leader in precision oncology for breast cancer, recently presented research introducing its investigational artificial intelligence (AI)-driven digital pathology approach for the MammaPrint®70-gene recurrence signature at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid. The podium presentation, delivered by co-founder and Chief Research Officer, Laura van ’t Veer, Ph.D., detailed the development and clinical validation of a deep learning pipeline that can infer MammaPrint (MP) risk categories directly from hematoxylin and eosin (H&E)-stained, whole-slide images (WSIs). The company also presented two additional posters highlighting data from the prospective, real-world FLEX Study (NCT03053193). “AI has been part of Agendia’s scientific fo
C.H. Robinson Debuts Lean AI for Ocean Shipping, Air Freight and Customs26.10.2026 13:00:00 CET | Press release
Global logistic provider’s fleet of AI agents grows, bringing greater speed, precision and agility to supply chains around the world As the global leader in Lean AI, C.H. Robinson has launched new AI agents that perform work in ocean shipping, air freight and customs brokerage. They represent an expansion of the company’s Lean AI capabilities into freight forwarding, for the benefit of more customers, and into work so complex that a single shipping task can require over a dozen AI agents working in tandem. Continuing to disrupt itself and the industry, the company’s new tech brings substantial speed-to-market gains, precision and agility to customers’ supply chains without sacrificing human oversight or personal attention. The new tech includes: Price-quoting for ocean and air cargo: AI has determined and delivered over 80,000 price quotes for over 3,600 customers. Quotes that used to take a day for an air shipment and two to three days for an ocean shipment now take two to three minut
TVS Motor Company Returns to EICMA With New Models for Europe26.10.2026 12:45:00 CET | Press release
A year after its Milan debut, TVS Motor returns with a rapidly expanding European footprint and Italian sales up 110%Peyman Kargar to lead TVS Motor’s next phase of global growth as the company expands European footprint TVS Motor Company (TVSM), a global leader in two- and three-wheeler manufacturing, returns to EICMA in Milan this November, one year after its debut at the world’s largest two-wheeler exhibition. The company will present new models for Europe at a press conference on Tuesday, 3 November at 10:00 CET. The TVS stand is in Hall 18, Stand I64. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026990290/en/ TVS Motor Company will present new models for Europe at a press conference on Tuesday, 3 November at 10:00 CET at EICMA this year. EICMA 2025 marked the beginning of TVS Motor's European growth journey. Since then, the company has focused on establishing the foundations for long-term success, building its deal
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 12:00:00 CET | Press release
Improvements in symptoms of pain, stiffness, and range of motion were sustained through two yearsTumor responses remained robust1 and durable2Not intended for U.K.-, U.S.- or Canada-based media Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom